Zacks.com on MSN12d
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...
Cure Today12d
Sasanlimab Improves Event-Free Survival for Some With Bladder Cancer
The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
GlobalData on MSN12d
Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or ...
Pharmabiz12d
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer
Pfizer Inc. announced positive topline results from its pivotal phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette ...
Targeted Oncology12d
Sasanlimab Plus BCG Demonstrates EFS Benefit in NMIBC
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
Nasdaq12d
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-naïve, high-risk, non-muscle invasive ...
Morningstar15d
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...